ATE300291T1 - Behandlung von krebs mit tetraethylthiuramdisulfid - Google Patents

Behandlung von krebs mit tetraethylthiuramdisulfid

Info

Publication number: ATE300291T1
Authority: AT; Austria
Prior art keywords: disulfide; tetraethylthiurame; treating cancer; tetraethylthiuram disulfide; growth
Prior art date: 1999-09-08

Application number

AT99963914T

Other languages

English (en)

Inventor

Thomas Preston Kennedy

Original Assignee

Charlotte Mecklenburg Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-08

Filing date

1999-11-15

Publication date

2005-08-15

1999-11-15 Application filed by Charlotte Mecklenburg Hospital filed Critical Charlotte Mecklenburg Hospital

2005-08-15 Application granted granted Critical

2005-08-15 Publication of ATE300291T1 publication Critical patent/ATE300291T1/de

Links

BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 abstract 4
102100023321 Ceruloplasmin Human genes 0.000 abstract 1
108010075016 Ceruloplasmin Proteins 0.000 abstract 1
JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
230000005907 cancer growth Effects 0.000 abstract 1
DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 abstract 1
229910001431 copper ion Inorganic materials 0.000 abstract 1
239000012990 dithiocarbamate Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229910001385 heavy metal Inorganic materials 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
150000002500 ions Chemical class 0.000 abstract 1
229940127084 other anti-cancer agent Drugs 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
- C12Y116/03—Oxidoreductases oxidizing metal ions (1.16) with oxygen as acceptor (1.16.3)
- C12Y116/03001—Ferroxidase (1.16.3.1), i.e. ceruloplasmin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT99963914T 1999-09-08 1999-11-15 Behandlung von krebs mit tetraethylthiuramdisulfid ATE300291T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/392,122 US6589987B2 (en)	1998-09-08	1999-09-08	Method of treating cancer using tetraethyl thiuram disulfide
PCT/US1999/027193 WO2001017522A1 (en)	1999-09-08	1999-11-15	Method of treating cancer using tetraethyl thiuram disulfide

Publications (1)

Publication Number	Publication Date
ATE300291T1 true ATE300291T1 (de)	2005-08-15

Family

ID=23549328

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99963914T ATE300291T1 (de)	1999-09-08	1999-11-15	Behandlung von krebs mit tetraethylthiuramdisulfid

Country Status (9)

Country	Link
US (1)	US6589987B2 (de)
EP (1)	EP1214063B1 (de)
JP (1)	JP2003514769A (de)
AT (1)	ATE300291T1 (de)
AU (1)	AU782029B2 (de)
CA (1)	CA2384059C (de)
DE (1)	DE69926407T2 (de)
ES (1)	ES2244237T3 (de)
WO (1)	WO2001017522A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7816403B2 (en) *	1998-09-08	2010-10-19	University Of Utah Research Foundation	Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
US6548540B2 (en) *	1998-09-08	2003-04-15	Charlotte-Mecklenburg Hospital Authority	Method of treating cancer using dithiocarbamate derivatives
AU2002226650A1 (en) *	2001-01-18	2002-07-30	Arnold Hoffman	Redox therapy for tumors
US20030073609A1 (en) *	2001-06-29	2003-04-17	Pinkerton Thomas C.	Enhanced pharmacokinetic profile of intradermally delivered substances
US7638331B2 (en)	2004-01-02	2009-12-29	The Administration of the Tulane Rducation Fund	Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
WO2006104396A1 (en) *	2005-03-26	2006-10-05	Protemix Corporation Limited	Pre-complexed copper antagonist compositions
WO2008068746A2 (en) *	2006-12-04	2008-06-12	Yeda Research And Development Co. Ltd.	Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
WO2008089440A2 (en)	2007-01-18	2008-07-24	University Of Utah Research Foundation	Compositions and methods for detecting, treating, or preventing reductive stress
US20110206756A1 (en) *	2008-03-17	2011-08-25	University Of Utah Research Foundation	Dithiocarbamate metal chelates and methods of making and using thereof
GB201020860D0 (en) *	2010-12-09	2011-01-26	Univ Wolverhampton	Disulfiram formulation and uses thereof
WO2014152207A1 (en)	2013-03-15	2014-09-25	Mylan Laboratories, Inc.	Hot melt granulation formulations of poorly water-soluble active agents
US20160303242A1 (en)	2013-12-09	2016-10-20	Durect Corporation	Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
WO2017049529A1 (en)	2015-09-24	2017-03-30	Innolife Co., Ltd.	A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
EP3311843A1 (de) *	2016-10-13	2018-04-25	Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts	Zusammensetzungen enthaltend dithiocarbamat und cyclodextrin
US10322096B2 (en)	2016-10-26	2019-06-18	Cantex Pharmaceuticals, Inc.	Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
ES2877149T3 (es)	2017-09-26	2021-11-16	Palacky Univ In Olomouc	Nanopartículas de complejo ditiocarbamato-metal biodisponibles, método de preparación y uso de las mismas
KR20190056758A (ko)	2017-11-17	2019-05-27	주식회사 지뉴브	종양줄기세포 특성의 암을 치료하기 위한 항암 병용 요법
EP3693740A1 (de) *	2019-02-07	2020-08-12	Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts	Verbesserte dithiocarmabatbasierende verbindungen, therapien und diagnostik
CN111135175B (zh) *	2020-01-17	2022-09-16	中国医学科学院放射医学研究所	Dsf-2在制备抗肿瘤和抗辐射药物中的应用
WO2021257880A1 (en) *	2020-06-18	2021-12-23	Spring Discovery, Inc.	Use of aldh modulators or gasdermin d inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system
US11351128B1 (en) *	2021-05-13	2022-06-07	Lance L. Gooberman	Pharmaceutical compositions and methods of administration
CN114010624B (zh) *	2021-12-13	2023-03-28	上海纳米技术及应用国家工程研究中心有限公司	双硫仑和甲氨蝶呤在制备抗肝癌药物中的应用
TWI854801B (zh) *	2022-08-29	2024-09-01	石貴中	醫藥組合物及其用途
TW202502312A (zh) *	2023-07-14	2025-01-16	石貴中	組合物及其用於動物之用途
CN121087625A (zh) *	2025-08-30	2025-12-09	康龙化成(宁波)科技发展有限公司	一种制备On-DNA二硫代氨基甲酸酯结构化合物的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4148885A (en)	1973-09-25	1979-04-10	Institut Merieux	Immunostimulant medicine
US4426372A (en)	1980-08-08	1984-01-17	Regents Of The University Of Minnesota	Inhibition of undesired effects of platinum(II) compounds
US4594238A (en)	1980-08-08	1986-06-10	Regents Of University Of Minnesota	Inhibition of undesired effect of platinum compounds
US4581224A (en)	1980-08-08	1986-04-08	Regents Of The University Of Minnesota	Inhibition of undesired effect of platinum compounds
US4762705A (en)	1981-11-10	1988-08-09	Adolf W. Schwimmer	Cancer therapy with interferon
US4645661A (en)	1984-06-29	1987-02-24	St. Jude Children's Research Hospital	Method for alleviating cisplatin-induced nephrotoxicity and dithiocarbamate compounds for effecting same
US5035878A (en)	1988-09-12	1991-07-30	University Of Rochester	Use of dithiocarbamates to counteract myelosuppression
US5187193A (en)	1988-09-12	1993-02-16	University Of Rochester	Method for stimulating transplanted bone marrow cells
JPH04202139A (ja)	1990-11-30	1992-07-22	Tosoh Corp	血管新生抑制剤
AU665599B2 (en)	1991-11-08	1996-01-11	Hemosol Inc.	Hemoglobins as drug delivery agents
US5380747A (en)	1992-10-30	1995-01-10	Emory University	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5783596A (en)	1992-10-30	1998-07-21	Emory University	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5807884A (en)	1992-10-30	1998-09-15	Emory University	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5786344A (en)	1994-07-05	1998-07-28	Arch Development Corporation	Camptothecin drug combinations and methods with reduced side effects
US5792787A (en)	1995-06-07	1998-08-11	Emory University	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
CA2269838A1 (en)	1996-11-06	1998-05-14	Morris D. Faiman	Method for treatment of glutamate related disorders
IL122892A0 (en)	1998-01-11	1998-08-16	Yeda Res & Dev	Pharmaceutical compositions comprising a thiocarbamate
IL122891A0 (en)	1998-01-11	1998-08-16	Yeda Res & Dev	Pharmaceutical compositions comprising a thiocarbamate

1999
- 1999-09-08 US US09/392,122 patent/US6589987B2/en not_active Expired - Lifetime
- 1999-11-15 AT AT99963914T patent/ATE300291T1/de not_active IP Right Cessation
- 1999-11-15 DE DE69926407T patent/DE69926407T2/de not_active Expired - Lifetime
- 1999-11-15 WO PCT/US1999/027193 patent/WO2001017522A1/en not_active Ceased
- 1999-11-15 ES ES99963914T patent/ES2244237T3/es not_active Expired - Lifetime
- 1999-11-15 AU AU20255/00A patent/AU782029B2/en not_active Expired
- 1999-11-15 JP JP2001521313A patent/JP2003514769A/ja active Pending
- 1999-11-15 CA CA2384059A patent/CA2384059C/en not_active Expired - Lifetime
- 1999-11-15 EP EP99963914A patent/EP1214063B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2244237T3 (es)	2005-12-01
DE69926407T2 (de)	2006-05-24
EP1214063A1 (de)	2002-06-19
CA2384059C (en)	2010-06-22
EP1214063B1 (de)	2005-07-27
US6589987B2 (en)	2003-07-08
WO2001017522A1 (en)	2001-03-15
DE69926407D1 (de)	2005-09-01
CA2384059A1 (en)	2001-03-15
AU782029B2 (en)	2005-06-30
AU2025500A (en)	2001-04-10
JP2003514769A (ja)	2003-04-22
US20030065026A1 (en)	2003-04-03

Legal Events

Date	Code	Title	Description
2006-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69926407D1 (de)	2005-09-01	Behandlung von krebs mit tetraethylthiuramdisulfid
DE60136730D1 (de)	2009-01-08	Methode zur behandlung von krebs mit dithiocarbamat-derivaten
DE60223262D1 (de)	2007-12-13	Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE363850T1 (de)	2007-06-15	Elektronenquelle für gerät zum behandeln von lebensmitteln und verfahren
MY140767A (en)	2010-01-15	Compounds, methods and compositions
ATE411016T1 (de)	2008-10-15	Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
DE60033658D1 (de)	2007-04-12	Behandlung von prostata-krebs mit anti-erbb2 antikörpern
WO2003075828A3 (en)	2003-12-24	Compounds useful in the treatment of cancer
ATE220560T1 (de)	2002-08-15	Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung.
ATE474946T1 (de)	2010-08-15	Elektrode für die behandlung von oberflächen mit elektrischen entladungen, verfahren zur behandlung von oberflächen mit elektrischen entladungen und vorrichtung zur behandlung von oberflächen mit elektrischen entladungen
AU2003273176A8 (en)	2003-12-12	Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
DE60120162D1 (en)	2006-07-06	Polyamin-analoge als cytotoxische wirkstoffe
IL124015A0 (en)	1999-01-26	Pharmaceutical compositions comprising a protein
ZA202406390B (en)	2025-05-28	Compounds and their use in treating cancer
ATE272404T1 (de)	2004-08-15	Verwendung von taurolidine zur herstellung eines arzneimittels zur behandlung von leukämien
WO2003073857A3 (de)	2004-02-12	Biologisch aktive kupferorganische mittel
NO20050640L (no)	2005-03-22	Rutenium anticancer komplekser
MX2025013372A (es)	2025-12-01	Inhibidores de gsk3\03b1 y metodos de uso de estos
DE69815840D1 (de)	2003-07-31	Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
DE59900286D1 (de)	2001-10-31	Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
WO2023158783A3 (en)	2023-09-28	Methods, compositions, and combinations for preventing or treating cancer recurrence
MXPA03006742A (es)	2003-10-24	Uso de buprenorfina para la terapia de la incontinencia urinaria.
ATE358495T1 (de)	2007-04-15	Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
WO2023150559A3 (en)	2023-09-28	Treatment of ovarian cancer with nirogacestat
DE60220504D1 (en)	2007-07-19	Tryptasehemmer